Future studies should investigate the relevance of miR-34a-5p targeting NFE2L2 and evaluate the therapeutic feasibility of GA or its derivatives in the setting of T2DM and steatohepatitis. The gene discussed is NFE2L2; the disease is type 2 diabetes mellitus.